Skip to main content
HCPCS J0695 · Level II · Part B drug

J0695: ceftolozane (Zerbaxa), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0695

Billing unit
75mg (50mg cft/25mg taz)
Inj ceftolozane tazobactam
ASP payment limit
$10.015
October 2026; -0.2% vs July 2026
Practitioner MUE
60
MAI 3
OPPS status
SI K
APC 9452
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J0695 is the Level II code for Injection, ceftolozane 50 mg and tazobactam 25 mg, billed per 75mg (50mg cft/25mg taz). The Medicare Part B ASP payment limit for October 2026 is $10.015 per billing unit, down 0.2% from July 2026. The practitioner MUE allows up to 60 units per date of service (MAI 3), so a full 60-unit day is $600.90 at the current limit. Under OPPS it carries status indicator K in APC 9452. J0695 is billed in units of 75mg (50mg cft/25mg taz); the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Zerbaxa by Merck Sharp & Dohme LLC. No current Billing and Coding Article lists J0695, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0695 at $10.015 per 75mg (50mg cft/25mg taz) for October 2026, derived from manufacturer average sales price plus 6%, compared with $10.038 in July 2026. Beneficiary coinsurance is 17%.

ASP payment limits for J0695
QuarterPayment limitPerCoinsurance
October 2026$10.01575mg (50mg cft/25mg taz)17%
July 2026$10.03875mg (50mg cft/25mg taz)—
CMS note: Inflation-adjusted coinsurance

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J0695. Report the NDC in the claim's drug segment and bill the number of J0695 units that equals the quantity administered divided by 75mg (50mg cft/25mg taz); the last column gives units per full package.

NDCs that crosswalk to J0695
NDCDrug nameLabelerPackage sizeBilling units / package
67919-0030-01ZerbaxaMerck Sharp & Dohme LLC1 × 10200

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J0695. For practitioners the limit is 60 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J0695 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services603 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital603 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J0695 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0695 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0695 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0695 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J0695 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0695 carries status indicator K and is assigned to APC 9452, with a published national unadjusted payment of $10.015. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0695 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $10.02 per 75mg (50mg cft/25mg taz), paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J0695 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0695

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0695

What does HCPCS code J0695 describe?

J0695 is defined by CMS as "Injection, ceftolozane 50 mg and tazobactam 25 mg". Each billing unit represents 75mg (50mg cft/25mg taz), so the units reported on the claim must equal the dose administered divided by that unit.

Is J0695 a CPT code?

No. J0695 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as ceftolozane (Zerbaxa); CPT codes are five-character codes maintained by the AMA. On a Part B claim J0695 reports the drug itself in 75mg (50mg cft/25mg taz) units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0695 in October 2026?

The ASP-based payment limit is $10.015 per 75mg (50mg cft/25mg taz), with 17% beneficiary coinsurance. The July 2026 limit was $10.038. Commercial payers use their own fee schedules.

How many units of J0695 can be billed per day?

The practitioner Medically Unlikely Edit is 60 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J0695?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Zerbaxa (Merck Sharp & Dohme LLC). For example NDC 67919-0030-01 (package size 1) equals 200 billing units of J0695.

Does J0695 have NCCI bundling edits?

No active practitioner PTP pairs list J0695 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.